Lisaftoclax: First Approval

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Lisaftoclax is a novel B-cell lymphoma 2 (BCL-2) inhibitor developed for hematological malignancies.
• It is administered via a 5-day ramp-up dosing schedule, reaching the target dose on day 6.
• The drug targets BCL-2, a protein implicated in cancer cell survival.

Purpose of the Study:

• To summarize the key development milestones of lisaftoclax.
• To detail the path leading to its first regulatory approval.
• To highlight the drug's initial indication for specific hematological cancers.

Main Methods:

• Review of preclinical and clinical development data for lisaftoclax.
• Analysis of regulatory submission and approval processes.
• Summary of clinical trial outcomes relevant to the approved indication.

Main Results:

• Lisaftoclax received its first approval on July 10, 2025, in China.
• The approval is for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
• Patients must have received at least one prior systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

Conclusions:

• The approval of lisaftoclax represents a significant advancement in treating relapsed/refractory CLL/SLL.
• This milestone validates the therapeutic potential of BCL-2 inhibition in hematological cancers.
• Further development and exploration of lisaftoclax in other hematological malignancies are anticipated.